Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Shared Insights on Treating BRAF
V600
-mutant Metastatic Cancers
September 2024
Shared Perspectives on Targeted Therapies for Metastatic BRAFV600 Mutations. Recorded live from Barcelona, Spain, during the 2024…
Read more
23rd July 2015
Phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Nicholas Turner, MD, PhD, of the Institute of Cancer Research and Royal Marsden…
13th July 2015
The impact of the Oncotype DX® Recurrence Score® on treatment decisions in breast cancer patients
The results of the Oncotype DX® Breast Cancer Assay are reported as a Recurrence Score® – a number ranging from 0 to 100. This number indicates the…
10th July 2015
Molecular characterisation of kidney cancer and opportunities for targeted therapies
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA…
10th July 2015
Emerging targeted therapies in haematological malignancies
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE…
10th July 2015
New strategies in the treatment of multiple myeloma
Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, reviews the new data presented at the 2015 American Society of Clinical…
10th July 2015
STRIDE: Phase 2 study of sipuleucel-T in metastatic castration-resistant prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…
10th July 2015
Julie M. Vose, MD, MBA, FASCO, elected ASCO President for 2015–2016 term
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 2015–2016 term, Julie M. Vose, MD, MBA, of the…
10th July 2015
Towards targeted therapy of chronic lymphocytic leukaemia
Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY, summarises recent progress in the treatment of chronic lymphocytic…
Loading posts...
« Previous
1
…
32
33
34
35
36
…
42
Next »